{"id":"sequential-therapy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sequential therapy is a treatment strategy rather than a single drug entity, involving the administration of different therapeutic agents one after another according to a defined protocol. This approach allows for dose optimization, assessment of response between phases, and potential reduction of cumulative toxicity compared to concurrent administration. The specific mechanism depends entirely on the individual drugs used in the sequence.","oneSentence":"Sequential therapy refers to a treatment approach that administers multiple therapeutic agents in a planned sequence rather than simultaneously, optimizing efficacy and tolerability.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:07:28.863Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06498648","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-18","conditions":"Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma","enrollment":74},{"nctId":"NCT07276360","phase":"PHASE2","title":"Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda","status":"RECRUITING","sponsor":"Uganda Cancer Institute","startDate":"2026-03-11","conditions":"Cervical Cancer, Cervix Cancer, Cervical Adenocarcinoma","enrollment":278},{"nctId":"NCT07074756","phase":"NA","title":"A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-09-12","conditions":"Glioma, Recurrent Glioma","enrollment":120},{"nctId":"NCT06192758","phase":"NA","title":"Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2024-04-15","conditions":"Prostate, Cancer","enrollment":36},{"nctId":"NCT04235777","phase":"PHASE1","title":"Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":"Urothelial Cancer, Bladder Cancer, Genitourinary Cancer","enrollment":100},{"nctId":"NCT07112963","phase":"NA","title":"\"Comparison of the Effects of Resin Infiltrant, Fluoride Varnish, and the Combined Application of Resin Infiltrant and Fluoride Varnish on Primary Molars in the Treatment of Proximal Non-Cavitated Carious Lesions in Children.\"","status":"COMPLETED","sponsor":"Sacide Duman","startDate":"2023-10-04","conditions":"Dental Caries, Tooth Demineralization, Pediatric Dentistry","enrollment":26},{"nctId":"NCT07497607","phase":"PHASE2","title":"Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sara Medek","startDate":"2026-06-01","conditions":"Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":31},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":"Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":1210},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT07492771","phase":"PHASE1","title":"MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"MicrobiotiX Co., Ltd","startDate":"2026-03","conditions":"Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection","enrollment":18},{"nctId":"NCT04670679","phase":"PHASE1","title":"A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasca, Inc.","startDate":"2020-12-15","conditions":"Advanced or Metastatic Solid Tumors","enrollment":90},{"nctId":"NCT06992609","phase":"PHASE3","title":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-15","conditions":"Small Cell Lung Carcinoma","enrollment":70},{"nctId":"NCT07493070","phase":"NA","title":"Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2026-02-10","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":30},{"nctId":"NCT07492914","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-20","conditions":"Resected Head and Neck Cancer","enrollment":30},{"nctId":"NCT05825066","phase":"PHASE2","title":"Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-08-01","conditions":"Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma","enrollment":64},{"nctId":"NCT07178366","phase":"NA","title":"Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-05-10","conditions":"Acute-on-Chronic Liver Failure (ACLF)","enrollment":56},{"nctId":"NCT07492342","phase":"PHASE2","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","status":"RECRUITING","sponsor":"Jianxing He","startDate":"2026-01-29","conditions":"Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC","enrollment":30},{"nctId":"NCT07491159","phase":"PHASE1, PHASE2","title":"Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-07-01","conditions":"Colorectal Cancer","enrollment":106},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT05758077","phase":"NA","title":"Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury","status":"RECRUITING","sponsor":"SeaStar Medical","startDate":"2023-04-17","conditions":"Acute Kidney Injury","enrollment":339},{"nctId":"NCT06314334","phase":"PHASE2","title":"Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-04","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":210},{"nctId":"NCT07094204","phase":"PHASE1","title":"A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2025-07-25","conditions":"Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma","enrollment":364},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT06432972","phase":"NA","title":"Accelerated Pulmonary Rehabilitation in the Preoperative Period","status":"RECRUITING","sponsor":"University of Vermont","startDate":"2024-01-02","conditions":"Chronic Obstructive Pulmonary Disease, Lung Cancer","enrollment":20},{"nctId":"NCT01297764","phase":"PHASE1, PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2011-04","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT06450041","phase":"PHASE2","title":"NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial","status":"RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2024-12-16","conditions":"Neuroblastoma","enrollment":62},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT06390293","phase":"NA","title":"The Effectiveness of Group-Delivered Guided Written Exposure Therapy for PTSD and CPTSD Among Chinese Adolescents","status":"COMPLETED","sponsor":"Peking University","startDate":"2024-05-01","conditions":"PTSD","enrollment":53},{"nctId":"NCT06788548","phase":"NA","title":"Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-02-03","conditions":"Early Gastric Cancer","enrollment":312},{"nctId":"NCT07486791","phase":"NA","title":"A Clinical Study on the Effect of Cardiopulmonary Function and Quality of Life in Patients With Acute Coronary Syndrome Complicated by Heart Failure by \"Lying-Sitting-Standing\" Sequential Baduanjin","status":"NOT_YET_RECRUITING","sponsor":"Xiling Qi","startDate":"2026-03-10","conditions":"ACS (Acute Coronary Syndrome), HF - Heart Failure","enrollment":65},{"nctId":"NCT04649242","phase":"PHASE3","title":"Randomized Study in Children and Adolescents With Migraine: Acute Treatment","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-01-15","conditions":"Pediatric Migraine","enrollment":2100},{"nctId":"NCT06881134","phase":"NA","title":"Rehabilitation Combining Spatiotemporal Spinal Cord Stimulation and Real-time Triggering Exoskeleton After Spinal Cord Injury","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-13","conditions":"Spinal Cord Injury, Neuromodulation, Robot Assisted Gait Training","enrollment":10},{"nctId":"NCT06898450","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Nimbus Wadjet, Inc.","startDate":"2025-03-31","conditions":"Advanced Solid Tumors Cancer, MSI-H Cancer","enrollment":134},{"nctId":"NCT05981703","phase":"PHASE1","title":"A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-09-21","conditions":"Advanced Solid Tumor, Solid Tumor","enrollment":217},{"nctId":"NCT06589596","phase":"PHASE1","title":"An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-10-11","conditions":"Advanced Solid Tumor","enrollment":244},{"nctId":"NCT06596473","phase":"PHASE1","title":"A Study of BG-C477 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-10-03","conditions":"Advanced Solid Tumors","enrollment":310},{"nctId":"NCT07159841","phase":"PHASE2, PHASE3","title":"A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2026-01-22","conditions":"Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia","enrollment":153},{"nctId":"NCT06071312","phase":"PHASE1, PHASE2","title":"FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-09-23","conditions":"Clostridium Difficile, Ulcerative Colitis","enrollment":64},{"nctId":"NCT07483333","phase":"NA","title":"Comparative Effectiveness of SPARCS and Unified Protocol for Youth With Chronic Medical Conditions and Trauma-Related Distress","status":"NOT_YET_RECRUITING","sponsor":"Anthony Vesco","startDate":"2026-07","conditions":"Trauma Exposure, Trauma, Trauma and Stressor Related Disorder","enrollment":400},{"nctId":"NCT06585488","phase":"PHASE1","title":"A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-11-26","conditions":"Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer","enrollment":514},{"nctId":"NCT06120283","phase":"PHASE1","title":"BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2023-12-01","conditions":"Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT05806931","phase":"PHASE2","title":"Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-05-17","conditions":"Colon Cancer, Rectal Cancer","enrollment":50},{"nctId":"NCT07222267","phase":"PHASE1","title":"An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-12-11","conditions":"Breast Cancer, Advanced Solid Tumor","enrollment":86},{"nctId":"NCT07015944","phase":"NA","title":"Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan","status":"RECRUITING","sponsor":"Pakistan Institute of Living and Learning","startDate":"2025-06-13","conditions":"Major Depressive Disorder (MDD), Breast Cancer Survivor","enrollment":26376},{"nctId":"NCT06980480","phase":"PHASE3","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-14","conditions":"Multiple Myeloma, Secondary Immunodeficiency","enrollment":183},{"nctId":"NCT06634589","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-11-27","conditions":"B-cell Malignancy, Relapsed Cancer, Refractory Cancer","enrollment":80},{"nctId":"NCT07480538","phase":"NA","title":"GCF Volume Changes in Aligners and Fixed Appliances","status":"COMPLETED","sponsor":"Suleyman Demirel University","startDate":"2025-06-03","conditions":"Orthodontic Tooth Movement","enrollment":32},{"nctId":"NCT04889716","phase":"PHASE2","title":"CAR-T Followed by Bispecific Antibodies","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-11-05","conditions":"Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT03795246","phase":"NA","title":"Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2018-04-12","conditions":"Breast Cancer","enrollment":132},{"nctId":"NCT06487858","phase":"PHASE1","title":"A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-07-16","conditions":"Solid Tumor","enrollment":75},{"nctId":"NCT05727189","phase":"PHASE1","title":"A Study of Idazoxan in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Terran Biosciences Australia Pty Ltd","startDate":"2023-02-14","conditions":"Healthy","enrollment":150},{"nctId":"NCT03835312","phase":"NA","title":"Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2019-02-20","conditions":"Diabetes Mellitus, Type 1, Immunologic Deficiency Syndromes","enrollment":50},{"nctId":"NCT06562907","phase":"PHASE1","title":"Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-28","conditions":"Weight Management","enrollment":134},{"nctId":"NCT07322263","phase":"PHASE2","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Michael A. O'Donnell","startDate":"2026-04-01","conditions":"Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma","enrollment":174},{"nctId":"NCT07318714","phase":"PHASE1, PHASE2","title":"A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke","status":"NOT_YET_RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2026-03-31","conditions":"Chronic Ischemic Stroke","enrollment":84},{"nctId":"NCT07478484","phase":"PHASE4","title":"Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB","status":"RECRUITING","sponsor":"Jing Zhou","startDate":"2026-03-31","conditions":"Ceftazidime-avibactam, Aztreonam, Gram-negative Bacterial Infection","enrollment":144},{"nctId":"NCT06540066","phase":"PHASE1","title":"A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2024-09-11","conditions":"Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer","enrollment":35},{"nctId":"NCT07287995","phase":"PHASE1, PHASE2","title":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-05","conditions":"Locally Advanced or Metastatic Malignant Solid Tumors","enrollment":428},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT06852170","phase":"NA","title":"Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention","status":"RECRUITING","sponsor":"Chestnut Health Systems","startDate":"2025-02-06","conditions":"Substance Abuse, Decision Making, Shared, Implementation Science","enrollment":341},{"nctId":"NCT07258407","phase":"PHASE1, PHASE2","title":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"T.O.A.D. Oncology SA","startDate":"2026-01-30","conditions":"Metastatic Castration-Resistant Prostatic Cancer","enrollment":180},{"nctId":"NCT07472478","phase":"PHASE2","title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-15","conditions":"Lung Cancer (NSCLC), KRAS G12C Lung Cancer","enrollment":32},{"nctId":"NCT06129864","phase":"PHASE3","title":"A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-14","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":1145},{"nctId":"NCT03607890","phase":"PHASE2","title":"Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-16","conditions":"Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors","enrollment":38},{"nctId":"NCT07426458","phase":"PHASE4","title":"Ventilation and Perfusion in Asthmatics","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04","conditions":"Asthma","enrollment":40},{"nctId":"NCT04273945","phase":"PHASE3","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-06-30","conditions":"Pulmonary Arterial Hypertension","enrollment":935},{"nctId":"NCT01614704","phase":"","title":"Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2011-10","conditions":"Breast Cancer, Fertility","enrollment":135},{"nctId":"NCT07179276","phase":"NA","title":"Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2026-03-15","conditions":"Sepsis - to Reduce Mortality in the Intensive Care Unit, Septic Shock","enrollment":750},{"nctId":"NCT07466056","phase":"","title":"Application of Non-inductive Intelligent Physical Sign Monitoring Equipment Based on Flexible Electronic Devices in the Diagnosis and Treatment of Cardiovascular Diseases","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-10-01","conditions":"Cardiovascular Disease","enrollment":1100},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT07459673","phase":"PHASE2","title":"HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-04","conditions":"Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV","enrollment":60},{"nctId":"NCT07387276","phase":"NA","title":"\"Recovery Techniques on Pain, Force and Muscle Oxygenation in Athletes: A Crossover Trial\"","status":"NOT_YET_RECRUITING","sponsor":"Sierra Varona SL","startDate":"2026-03-01","conditions":"Muscle Soreness, Delayed Onset Muscle Soreness, Athletic Injuries","enrollment":20},{"nctId":"NCT06382818","phase":"NA","title":"Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2025-03-06","conditions":"Breast Cancer","enrollment":854},{"nctId":"NCT06598800","phase":"PHASE1","title":"Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2024-10-18","conditions":"Advanced Solid Tumor","enrollment":87},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT06087536","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex","status":"RECRUITING","sponsor":"Omnix Medical Ltd","startDate":"2026-03","conditions":"Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia","enrollment":54},{"nctId":"NCT02991469","phase":"PHASE2","title":"A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2018-08-09","conditions":"Juvenile Idiopathic Arthritis","enrollment":51},{"nctId":"NCT02627196","phase":"NA","title":"Baroreflex Activation Therapy for Heart Failure","status":"COMPLETED","sponsor":"CVRx, Inc.","startDate":"2016-04-19","conditions":"Heart Failure","enrollment":1090},{"nctId":"NCT07459881","phase":"NA","title":"Effects of Combined Upper Extremity Exercise and Pneumatic Compression Therapy on Breast Cancer-Related Lymphedema","status":"NOT_YET_RECRUITING","sponsor":"Far Eastern Memorial Hospital","startDate":"2026-03","conditions":"Breast Cancer Lymphedema","enrollment":20},{"nctId":"NCT07304154","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-03","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis","enrollment":52},{"nctId":"NCT07460024","phase":"NA","title":"Implementation of Timely Management of Sepsis and Septic Shock Protocol in the Emergency Department and Intensive Care Unit: A Quality Improvement Project at AFHJ","status":"NOT_YET_RECRUITING","sponsor":"Al-Azhar University","startDate":"2026-03","conditions":"Sepsis, Septic Shock, Systemic Inflammatory Response Syndrome (SIRS)","enrollment":120},{"nctId":"NCT06343090","phase":"NA","title":"Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-04-12","conditions":"B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia","enrollment":353},{"nctId":"NCT03523702","phase":"PHASE2","title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2018-08-30","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":25},{"nctId":"NCT05669950","phase":"PHASE1, PHASE2","title":"A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia","status":"RECRUITING","sponsor":"H. Lundbeck A/S","startDate":"2022-12-19","conditions":"Congenital Adrenal Hyperplasia","enrollment":42},{"nctId":"NCT05514132","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-23","conditions":"Advanced Solid Tumours","enrollment":14},{"nctId":"NCT07458711","phase":"NA","title":"Comparative Effects of Spencer Techniques and Movement With Mobilization in Improving Pain, Range of Motion, and Functional Disability in Rotator Cuff Syndrome.","status":"COMPLETED","sponsor":"University of Lahore","startDate":"2025-09-26","conditions":"Rotator Cuff Syndrome","enrollment":60},{"nctId":"NCT06326008","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2026-03-15","conditions":"B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse","enrollment":48},{"nctId":"NCT07459504","phase":"PHASE2","title":"SMART Diets for MASLD","status":"NOT_YET_RECRUITING","sponsor":"Corewell Health West","startDate":"2026-04-26","conditions":"Metabolic-dysfunction Associated Steatotic Liver Disease","enrollment":102},{"nctId":"NCT07453394","phase":"PHASE1, PHASE2","title":"QLS5132 Combination Therapy in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer","enrollment":626},{"nctId":"NCT07453875","phase":"PHASE1","title":"LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-02-09","conditions":"Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT","enrollment":9},{"nctId":"NCT02703623","phase":"PHASE2","title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-18","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma","enrollment":196},{"nctId":"NCT07443826","phase":"PHASE1, PHASE2","title":"CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy","status":"RECRUITING","sponsor":"Unlimited Biotechnology LLC","startDate":"2026-03-31","conditions":"Age-related Muscle Decline","enrollment":12},{"nctId":"NCT05318534","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease","status":"RECRUITING","sponsor":"Gliknik Inc.","startDate":"2022-04-08","conditions":"First in Man Study to Evaluate Initial Safety","enrollment":70},{"nctId":"NCT02354014","phase":"PHASE2","title":"Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2016-05-03","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":60},{"nctId":"NCT01928589","phase":"NA","title":"Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Richard Zellars","startDate":"2014-01-16","conditions":"Breast Cancer, Adenocarcinoma of the Breast","enrollment":81},{"nctId":"NCT01349322","phase":"PHASE3","title":"Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2011-05-24","conditions":"Breast Cancer","enrollment":2354},{"nctId":"NCT07428018","phase":"PHASE2","title":"Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-04-30","conditions":"Breast Cancer, HER2 + Breast Cancer, HR Positive","enrollment":150},{"nctId":"NCT07450352","phase":"PHASE2","title":"SEED-CRYO: Sequential 125I Seed Implantation Followed by Cryoablation vs Single-Modality Local Therapy in Unresectable Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Li Min","startDate":"2026-02","conditions":"Unresectable Solid Tumors","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2461,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Omeprazole-Amoxicillin-Clarithromycin-Metronidazole","Amoxicillin 1000 mg orally twice daily for 5 days","Omeprazole 20 mg orally twice daily for 5 days","Then","Clarithromycin 500 mg orally twice daily for 5 days"],"phase":"marketed","status":"active","brandName":"Sequential therapy","genericName":"Sequential therapy","companyName":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","companyId":"irccs-azienda-ospedaliero-universitaria-di-bologna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}